Naltrexone (mu-opioid reward blockade) vs acamprosate (glutamate/GABA excitability dampening) — two contrasting pharmacologies for maintaining alcohol abstinence
Acute alcohol withdrawal is only the first hurdle. Once benzodiazepine-assisted detoxification is complete and the patient is medically stable, the brain remains in a state of profound neuroadaptive imbalance: mesolimbic dopamine reward circuits are sensitized toward alcohol-associated cues, while cortical and limbic glutamate signaling — chronically upregulated to compensate for alcohol's GABA-potentiating, NMDA-suppressing effects — is now unopposed and hyperexcitable. This is precisely the window in which a maintenance medication should be started, because relapse risk is highest in the first weeks to months after withdrawal.
Chronic alcohol exposure produces two durable neuroadaptations that persist well past acute withdrawal, and each maintenance medication targets one of them:
1. Sensitized reward circuitry — repeated alcohol-induced dopamine release in the ventral tegmental area / nucleus accumbens pathway strengthens cue-reward associations. Even the sight of a bar or a beer advertisement can trigger anticipatory dopamine firing. This is the substrate naltrexone acts on: block the mu-opioid receptors that normally amplify VTA dopamine release, and the reinforcing "high" from a drink is blunted at the source.
2. Glutamate/GABA imbalance — chronic alcohol potentiates GABA-A inhibition and suppresses NMDA-mediated glutamate transmission; the brain compensates by upregulating glutamate receptors and downregulating GABA-A sensitivity. When alcohol is removed, this compensation is unmasked as excess excitatory tone — the neurophysiological substrate of protracted craving, anxiety, insomnia, and dysphoria that can persist for weeks. This is the substrate acamprosate acts on: it normalizes glutamatergic hyperactivity so the system does not have to "self-medicate" with alcohol to feel calm.
Critically, these are not competing theories of the same problem — they describe two separable circuits that both drive drinking behavior, which is why the mechanisms are complementary rather than redundant.
Neither medication treats acute withdrawal itself — benzodiazepines remain first-line for that. Maintenance medication is started once the patient is medically stable, typically the same admission or within the first two weeks after detox, because:
• Craving during the post-acute withdrawal window is a leading predictor of early relapse • Habit and cue-reactivity strengthen the longer an unmedicated patient is exposed to triggers • Acamprosate's benefit is largest when started as early as possible after the patient has already stopped drinking — it does not treat active drinking • Naltrexone can, by contrast, be started even if the patient has not achieved full abstinence, since it works by blunting reward during any subsequent drinking rather than requiring a sober baseline
A useful framing for trainees: acamprosate is a relapse-prevention medication for someone who has already stopped drinking, while naltrexone is a harm-reduction and relapse-prevention medication that works whether or not the patient has fully stopped. Choosing between them starts with asking "has this patient already achieved abstinence, or are we still trying to get them there?"
Selecting naltrexone versus acamprosate is a patient-matching decision, not a coin flip. The two drugs have almost non-overlapping contraindication profiles and differing evidence for different drinking patterns, so a structured selection against renal/hepatic status, pain-management needs, and the patient's own drinking phenotype meaningfully changes expected outcomes.
Favors naltrexone: • Normal hepatic function (oral naltrexone is hepatically metabolized; avoid in acute hepatitis or hepatic failure — check LFTs first) • Heavy episodic / binge drinking pattern with strong craving-driven "can't stop once I start" phenotype — naltrexone reliably reduces heavy-drinking days and the reinforcing value of continued drinking • Impaired renal function, since naltrexone does not require renal clearance the way acamprosate does • Available as oral daily tablet or once-monthly extended-release IM injection (XR-naltrexone / Vivitrol), which improves adherence significantly over daily oral dosing
Favors acamprosate: • Impaired hepatic function (acamprosate is not hepatically metabolized and is renally excreted unchanged — a cleaner choice in patients with liver disease, which is extremely common in alcohol use disorder) • Ongoing or anticipated need for opioid analgesics (post-surgical patients, chronic pain) — naltrexone's opioid blockade both precipitates withdrawal in opioid-dependent patients and defeats the analgesic effect of opioids if they are later required • Patient has already achieved abstinence and the goal is relapse prevention / staying sober, rather than reducing the intensity of drinking that is still occurring • Requires normal renal function (dose-reduce for CrCl 30–50 mL/min, contraindicated below 30 mL/min) — the mirror image of naltrexone's hepatic requirement
The two contraindication profiles are almost perfectly complementary: a patient who cannot safely take one is often a good candidate for the other.
This is one of the most clinically consequential distinctions between the two drugs. Naltrexone occupies and blocks mu-opioid receptors — the same receptors targeted by opioid analgesics. A patient on naltrexone who then needs opioids for acute pain (surgery, trauma, active cancer pain) will not get adequate analgesia at normal doses, and attempts to "break through" the blockade with high-dose opioids risk severe, unpredictable overdose once the antagonist eventually wears off. Oral naltrexone must be stopped roughly 72 hours and XR-naltrexone roughly 30 days before any elective procedure where opioid analgesia is anticipated. Acamprosate has no interaction with the opioid system whatsoever, which makes it the default choice for patients with anticipated surgery, chronic pain conditions, or a history of comorbid opioid use.
The dual-pathway animation makes the mechanisms visually literal. On the reward side, a drink cue triggers a burst of dopamine particles traveling from the trigger toward the reward center (nucleus accumbens); naltrexone erects a receptor blockade that deflects most of these particles before they arrive, producing a measurable "reward signal blunted" percentage. On the excitability side, a glutamate/GABA balance oscillator wobbles erratically at baseline; acamprosate applies a damping force that narrows the oscillation, producing a "neuroexcitability stabilized" percentage.
Alcohol triggers release of endogenous opioids (beta-endorphin) in the ventral tegmental area, which disinhibits dopamine neurons and amplifies dopamine release in the nucleus accumbens — this is the proximate mechanism of alcohol's reinforcing "high." Naltrexone is a competitive mu-opioid receptor antagonist: it occupies these receptors and prevents beta-endorphin from disinhibiting the dopamine neurons, so a drink that would normally produce a strong reward signal instead produces a muted one. Behaviorally, this does not prevent the first drink, but it reliably reduces the reinforcing pull to keep drinking once started — which is why naltrexone's strongest evidence is for reducing heavy-drinking days and converting binge episodes into lighter ones, rather than for maintaining total abstinence outright.
Acamprosate's exact mechanism is still incompletely characterized, but converging evidence points to modulation of the metabotropic glutamate receptor 5 (mGluR5) system, weak functional antagonism at NMDA receptors, and GABA-B receptor co-agonism. The net effect is a normalization of the glutamatergic hyperexcitability that persists after chronic alcohol exposure is removed. Rather than blunting a specific rewarding event, acamprosate lowers the background level of neuronal excitability that manifests as protracted craving, irritability, and anxiety in early abstinence — so its clinical signature is a smoother, less erratic recovery trajectory rather than a blunted response to any single drink.
The two mechanisms act on different variables in this simulation: naltrexone reduces the amplitude of the reward spike when a drinking event occurs, while acamprosate reduces the baseline volatility of the excitability oscillator between events. A patient could, in principle, benefit from both mechanisms simultaneously — which is the rationale behind combination-therapy trials.
Relapse rarely happens in a vacuum — it is precipitated by identifiable high-risk situations: negative affect and stress, social pressure to drink, and environmental cues (a familiar bar, the smell of alcohol, an argument). This stage fires simulated lightning-bolt triggers at a frequency set by the Cue/Stress Exposure slider and shows how each medication changes the probability that a trigger cascades into a heavy-drinking event.
Marlatt's classic relapse-prevention model identifies three dominant high-risk categories: negative emotional states, interpersonal conflict, and social pressure — together accounting for the majority of documented relapse episodes. Medication does not remove exposure to these situations; it changes the probability that exposure converts into a drinking event, and if drinking occurs, how far it escalates.
In this simulation, higher cue/stress intensity increases both the frequency and the size of triggering events. Under naltrexone, a triggered drinking event still occurs, but the resulting reward signal is blunted — behaviorally this corresponds to a lapse that is less likely to escalate into a prolonged binge, because the drink "isn't as rewarding as it used to be." Under acamprosate, the trigger itself produces a smaller excitability spike because baseline glutamatergic tone is already stabilized — behaviorally this corresponds to lower cue-triggered craving and anxiety in the first place, making the lapse itself less likely to be initiated.
Neither drug eliminates relapse risk under high-intensity exposure — both reduce it. Meta-analyses consistently show medication effect sizes are modest-to-moderate (numbers needed to treat around 10–12) and are substantially larger when paired with structured psychosocial treatment such as Cognitive Behavioral Therapy relapse-prevention skills, Motivational Enhancement Therapy, or Twelve-Step Facilitation. The COMBINE study (2006) found that naltrexone plus structured medical management performed comparably to naltrexone plus intensive combined behavioral intervention — but placebo plus behavioral intervention alone, and medication without any behavioral support, both underperformed the combined approaches. Medication changes the odds at the moment of exposure; psychosocial treatment changes how often and how severely the patient is exposed in the first place.
Over months of maintenance therapy, the two mechanisms translate into measurably different outcome curves: naltrexone's advantage is concentrated in reducing the number and severity of heavy-drinking days even among patients who have some drinking events, while acamprosate's advantage is concentrated in prolonging continuous abstinence once it has been achieved. Neither is dramatically more "effective" than the other in aggregate — they answer different clinical questions.
Cochrane systematic reviews (Rösner et al. and Jonas et al.) estimate naltrexone reduces the risk of returning to any heavy drinking with a number needed to treat of roughly 12, and reduces drinking days and craving scores across dozens of randomized trials, with the largest effect sizes in patients with a strong family history of alcoholism and craving-predominant phenotypes. Acamprosate reviews report a similar NNT of roughly 12 for preventing any return to drinking, with the largest effect in patients started shortly after achieving abstinence with a clear motivation to remain abstinent, and a much smaller or absent effect in patients who have not yet stopped drinking at treatment initiation.
The large COMBINE study (JAMA 2006, N=1383) directly compared naltrexone, acamprosate, combined behavioral intervention, and their combinations, and — somewhat surprisingly to the field — found no added benefit of combining naltrexone and acamprosate over naltrexone alone plus medical management. European trials using different populations and acamprosate-first protocols have shown more favorable acamprosate signal, illustrating that population and drinking-pattern differences materially affect which drug looks stronger in a given trial.
Disulfiram works through an entirely different, non-craving mechanism: it irreversibly inhibits aldehyde dehydrogenase, so any alcohol consumed cannot be fully metabolized and acetaldehyde accumulates, producing a rapid, unpleasant reaction — flushing, nausea, tachycardia, and hypotension. It does not reduce craving or reward at all; its efficacy is purely a deterrent contingent on the patient actually taking the pill and believing the reaction will occur if they drink. Because adherence is the rate-limiting factor and the medication does nothing pharmacologically once skipped, disulfiram's real-world effectiveness depends heavily on supervised or observed dosing (a partner, clinic, or contingency-management program watching administration), and it is generally reserved for highly motivated patients or those under structured supervision rather than used as a first-line agent.
Across every major trial in this field, medication alone underperforms medication paired with structured psychosocial care, and psychosocial care alone underperforms the combination. Practical prescribing guidance converges on a few themes: match the drug to the patient's hepatic/renal status and opioid needs; start as early as possible after detox; set the expectation that relapse-prevention medication reduces risk rather than eliminating it; and pair pharmacotherapy with counseling, mutual-help groups, or structured relapse-prevention skills training for the best realistic odds of sustained recovery.
No single number captures "which drug is better" — naltrexone and acamprosate were both approved on modest but real effect sizes, target different circuits, and are frequently the right choice for different patients rather than competitors for the same patient. The clinical skill is in matching mechanism to phenotype and contraindication profile, not in picking a universal winner.